So the [regulatory] discussion [for Ipilimumab] will about the appropriate label…
Maybe, but not necessarily. The regulatory discussion may also be about whether the FDA should insist on another trial before granting approval. You completely missed the point of this thread.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”